Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients DOI Creative Commons
Wei Hong, Xinyuan Zhang,

Youkun Qi

и другие.

Cancer Management and Research, Год журнала: 2024, Номер Volume 16, С. 1205 - 1213

Опубликована: Сен. 1, 2024

Purpose: Lung cancer remains a leading cause of cancer-related death and chemotherapy stands as fundamental component in therapy.Chemotherapy-induced myelosuppression encompasses spectrum hematological declines, including not only neutrophils but also lymphocytes, hemoglobin levels platelets.This retrospective cohort study investigates alterations peripheral blood lymphocyte subsets.By uncovering these changes, our goal is to refine patient management strategies, ensuring that the benefits are maximized while minimizing its detrimental effects.Patients Methods: We retrospectively analyzed 159 lung patients.Patients were categorized "NT" (n=108, no previous anti-tumor therapy), "PT" (n=51, prior therapy followed by at least two-month treatment-free interval).Postchemotherapy, patients reassessed grouped into "EarlyCycle" for those who underwent four or fewer cycles, "LateCycle" more than cycles. Results:The focused on analyzing percentages subsets, T cells (CD4+, CD8+), B cells, natural killer (NK) across groups.For EarlyCycle group exhibited significant increase compared NT (0.7783 vs 0.7271; p=0.0017) PT 0.6804; p=1.6e-05).B showed decrease from LateCycle (0.1014 0.0817; p=2.2e-05) (0.1317 p=6.2e-10).NK significantly decreased (0.1109 0.1462; p=0.00816) 0.1513; p=0.00992), with change either (p>0.05).Conclusion: Chemotherapy affects subsets treatment-specific manner.The experienced reduction NK cell an cell, suggesting damage innate immunity early shift towards adaptive immunity.The substantial indicating delayed effect humoral components.

Язык: Английский

Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study DOI Creative Commons
Dongdong Zhang,

Guichao Liu,

Jinhui Ye

и другие.

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 30, 2025

Multiple studies have demonstrated that the abundance and functionality of γδ T cells are favorable prognostic indicators for prolonged survival in cancer patients. However, association between immunophenotype circulating therapeutic response NSCLC patients undergoing chemotherapy or targeted therapy remains unclear. Patients with EGFR wild-type (EGFR-WT) mutant (EGFR-Mut) non-small cell lung (NSCLC), diagnosed January 2020 2024, were included this study. Clinicopathological characteristics, treatment regimens, follow-up data retrospectively collected. Peripheral blood samples from 52 analyzed immunophenotypes αβ using full-spectrum flow cytometry. No significant differences observed proportions cells, nor expression immune exhaustion markers, epidermal growth factor receptor Notably, a high clinical benefit rate (responder, R) exhibited higher proportion Vδ2 compared to non-responders (NR), both EGFR-Mut (NR vs. R, P = 0.0437) EGFR-WT groups 0.0180). Additionally, marker PD-1 on was significantly lower responder group EGFR-Mut, 0.0050; EGFR-WT, Moreover, elevated levels TNF-α non-responders, irrespective mutation status 0.0055; 0.0007). These findings collectively suggest low critical contributors effectiveness therapies NSCLC. Targeting may represent promising strategy enhancing rates

Язык: Английский

Процитировано

0
Interpretable Prediction of Lymphopenia Following Neo-Adjuvant Chemo-Radiotherapy for Rectal Cancer: An Analysis of the ARISTOTLE Randomised Phase III Trial DOI
Ying Zhang, Douglas Brand, Sumeet Hindocha

и другие.

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Diagnostic Efficacy and Clinical Significance of Lymphocyte Subsets, Granzyme B and Perforin in the Peripheral Blood of Patients with Invasive Breast Cancer Following Neoadjuvant Chemotherapy DOI Creative Commons
Han Liu,

Ruinian Zheng,

Zhaowei Zhuang

и другие.

Cancer Management and Research, Год журнала: 2025, Номер Volume 17, С. 589 - 602

Опубликована: Март 1, 2025

Breast cancer, a predominant contributor to cancer-related mortality worldwide, is increasingly managed through the application of neoadjuvant chemotherapy (NAC). Analyzing dynamic changes in peripheral blood lymphocyte subsets, granzyme B and perforin are crucial for investigating their roles tumorigenesis, development treatment; this study aimed use these analyses diagnose malignant breast tumor, assess anti-tumor immunity predict efficacy cancer patients. To address objective, total 582 samples were collected from healthy controls (n=47), benign disease patients (n=401) (n=134). Lymphocyte along with expression, assessed using flow cytometry. Changes before after NAC also monitored. exhibited reduced proportions absolute counts CD3+ CD8+ T cells, increased NK cell percentage CD4+/CD8+ ratio, higher levels CD3+, cells cells. Post-NAC, percentages CD4+, increased, while decreased compared pre-NAC. Furthermore, effective group showed lower than ineffective post-NAC. Incidentally, Granzyme expression was elevated following postoperative chemotherapy. These findings indicated that levels, could serve as potential biomarkers differentiating tumors, assessing predicting efficacy.

Язык: Английский

Процитировано

0
Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients DOI Creative Commons
Wei Hong, Xinyuan Zhang,

Youkun Qi

и другие.

Cancer Management and Research, Год журнала: 2024, Номер Volume 16, С. 1205 - 1213

Опубликована: Сен. 1, 2024

Purpose: Lung cancer remains a leading cause of cancer-related death and chemotherapy stands as fundamental component in therapy.Chemotherapy-induced myelosuppression encompasses spectrum hematological declines, including not only neutrophils but also lymphocytes, hemoglobin levels platelets.This retrospective cohort study investigates alterations peripheral blood lymphocyte subsets.By uncovering these changes, our goal is to refine patient management strategies, ensuring that the benefits are maximized while minimizing its detrimental effects.Patients Methods: We retrospectively analyzed 159 lung patients.Patients were categorized "NT" (n=108, no previous anti-tumor therapy), "PT" (n=51, prior therapy followed by at least two-month treatment-free interval).Postchemotherapy, patients reassessed grouped into "EarlyCycle" for those who underwent four or fewer cycles, "LateCycle" more than cycles. Results:The focused on analyzing percentages subsets, T cells (CD4+, CD8+), B cells, natural killer (NK) across groups.For EarlyCycle group exhibited significant increase compared NT (0.7783 vs 0.7271; p=0.0017) PT 0.6804; p=1.6e-05).B showed decrease from LateCycle (0.1014 0.0817; p=2.2e-05) (0.1317 p=6.2e-10).NK significantly decreased (0.1109 0.1462; p=0.00816) 0.1513; p=0.00992), with change either (p>0.05).Conclusion: Chemotherapy affects subsets treatment-specific manner.The experienced reduction NK cell an cell, suggesting damage innate immunity early shift towards adaptive immunity.The substantial indicating delayed effect humoral components.

Язык: Английский

Процитировано

0